Literature DB >> 25971575

Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population.

Helen K Reddel1, Susan M Sawyer2, Peter W Everett3, Paul V Flood3, Matthew J Peters4.   

Abstract

OBJECTIVE: To identify patterns of asthma control and treatment in Australian adults with asthma.
DESIGN: Cross-sectional web-based survey, conducted 1-27 November 2012. PARTICIPANTS: Adults with current asthma, at least 16 years of age, drawn randomly from a web-based panel and weighted to reflect national population proportions for people with asthma. MAIN OUTCOME MEASURES: Asthma Control Test (ACT) scores; health care utilisation; medication use.
RESULTS: 2686 participants completed the survey (57.1% female; median age group, 40-49 years). Mean ACT score was 19.2 (95% CI, 18.9-19.3), with asthma classified as "well controlled" for 54.4% of participants, "not well controlled" for 22.7% and "very poorly controlled" for 23.0%. 60.8% reported using preventer medication (mostly combined inhaled corticosteroid/long-acting β2-agonist) during the previous year. 23.4% had made at least one urgent visit to a general practitioner concerning their asthma, 10.0% at least one emergency department visit. Urgent consultations were more common for "very poorly controlled" than "well controlled" asthma (adjusted odds ratio, urgent GP visits 5.98 [95% CI, 4.75-7.54] and emergency department visits 2.59 [95% CI, 1.91-3.53] respectively). Participants were classified according to asthma symptom control and frequency of preventer medication usage: Those with "well controlled" asthma included Group A (40.0% of participants) who used preventer medication infrequently (less than 5 days a week) or not at all, consistent with mild asthma, and Group B (14.7%), who used it at least 5 days a week. Uncontrolled asthma symptoms were reported by Group C (19.7%) despite regular preventer use, and by Group D (25.7%), who used none or little.
CONCLUSIONS: This study provides the first data about asthma control and its relationship with treatment in a large representative Australian population. The findings highlight significant preventable asthma morbidity in Australia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25971575     DOI: 10.5694/mja14.01564

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  36 in total

1.  Validity and Reliability of the Assessment Tool for Asthma (ATA) Questionnaire: the ATA Study.

Authors:  Bilun Gemicioğlu; Dilşad Mungan; Sevim Bavbek; Füsun Yıldız; Mehmet Polatlı; Sibel Naycı; Ferda Öner Erkekol; Hatice Türker; Hakan Günen; Güngor Çamsarı; Öznur Abadoğlu; Arif Çımrın; A Berna Dursun; Özlem Göksel; Seçil Kepil Özdemir; Şermin Börekci; Ömür Aydın; Birsen Ocaklı; Aygün Gür; Arzu Baygul; Zeynep Mısırlıgil
Journal:  Turk Thorac J       Date:  2020-03-01

Review 2.  Pulmonary rehabilitation versus usual care for adults with asthma.

Authors:  Christian R Osadnik; Ciara Gleeson; Vanessa M McDonald; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2022-08-22

3.  Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects.

Authors:  Kerry L Hancock; Sinthia Bosnic-Anticevich; John D Blakey; Mark Hew; Li Ping Chung; Biljana Cvetkovski; Scott Claxton; Peter Del Fante; Eve Denton; Joe Doan; Kanchanamala Ranasinghe; Lucy Morgan; Anita Sharma; Peter K Smith; Deb Stewart; Philip J Thompson; Russell Wiseman; John W Upham; Kwok Y Yan; Victoria Carter; Kiranjeet Dhillon; Florian Heraud; Thao Le; Rebecca Vella; David Price
Journal:  Pragmat Obs Res       Date:  2022-07-05

4.  Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis.

Authors:  Tracey-Lea Laba; Helen K Reddel; Nicholas J Zwar; Guy B Marks; Elizabeth Roughead; Anthony Flynn; Michele Goldman; Aine Heaney; Kirsty Lembke; Stephen Jan
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

5.  Implementation of asthma guidelines to West Australian community pharmacies: an exploratory, quasi-experimental study.

Authors:  Kim Watkins; Michelle Trevenen; Kevin Murray; Peter A Kendall; Carl R Schneider; Rhonda Clifford
Journal:  BMJ Open       Date:  2016-08-31       Impact factor: 2.692

6.  Opportunities to develop the professional role of community pharmacists in the care of patients with asthma: a cross-sectional study.

Authors:  Kim Watkins; Aline Bourdin; Michelle Trevenen; Kevin Murray; Peter A Kendall; Carl R Schneider; Rhonda Clifford
Journal:  NPJ Prim Care Respir Med       Date:  2016-11-24       Impact factor: 2.871

7.  Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG.

Authors:  Karin Lisspers; Pedro Teixeira; Coert Blom; Janwillem Kocks; Björn Ställberg; David Price; Niels Chavannes
Journal:  NPJ Prim Care Respir Med       Date:  2016-04-14       Impact factor: 2.871

Review 8.  Elucidating novel disease mechanisms in severe asthma.

Authors:  Richard Y Kim; Brittany Rae; Rachel Neal; Chantal Donovan; James Pinkerton; Lohis Balachandran; Malcolm R Starkey; Darryl A Knight; Jay C Horvat; Philip M Hansbro
Journal:  Clin Transl Immunology       Date:  2016-07-15

9.  Level of asthma control and risk factors for poor asthma control among clinic patients seen at a Referral Hospital in Addis Ababa, Ethiopia.

Authors:  Tewodros H Gebremariam; Amsalu B Binegdie; Abebe S Mitiku; Aschalew W Ashagrie; Kibrom G Gebrehiwot; Dawit K Huluka; Charles B Sherman; Neil W Schluger
Journal:  BMC Res Notes       Date:  2017-11-06

10.  High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma.

Authors:  Anna Jetske Baron; Bertine M J Flokstra-de Blok; Huib A M Kerstjens; Gineke Koopmans-Klein; David B Price; Andrea A Sellink; Ioanna Tsiligianni; Janwillem W H Kocks
Journal:  J Asthma Allergy       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.